Yaz Pulmonary Embolism Victim Files Lawsuit
Kimberly Wagoner of Massachusetts has filed a Yasmin lawsuit after suffering injuries caused by her use of the popular contraceptive, manufactured by Bayer. Wagoner developed a Yaz pulmonary embolism during the year that she took the birth control, and has sued Bayer for failing to sufficiently warn patients and physicians of the dangerous side effects associated with Yaz and Yasmin. Wagoner’s lawsuit will join pending multidistrict litigation, a different form of mass litigation than a Yaz class action lawsuit.
Plaintiff alleges to suffer from Yaz pulmonary embolism
Wagoner developed a pulmonary embolism while taking the contraceptive, a condition that has caused her significant pain and suffering, as well as a host of medical bills. Her Yasmin lawsuit asserts that the embolism may continue to cause her problems well into the future.
Wagoner complains that had she been sufficiently warned of the risks of Yaz pulmonary embolism and related side effects, she would not have taken the birth control in the first place. Wagoner is not the only woman to suffer a pulmonary embolism. But rather than joining a Yaz class action lawsuit, she chose to file a separate Yasmin lawsuit that will be consolidated into multidistrict litigation (MDL 2100) in Illinois.
Yaz class action lawsuit vs. MDL
Unlike a Yaz class action lawsuit, the MDL allows plaintiffs to file their own individual lawsuit. The MDL consists of similar product liability litigation, consolidated to streamline the process and conserve defendants’ resources. Every related Yasmin lawsuit is consolidated into the MDL, and litigation undergoes pre-trial proceedings en masse. Each lawsuit then receives its own separate trial based on the specific instances of that plaintiff’s case.
Bayer faces accusations of concealing evidence
Wagoner’s Yasmin lawsuit accuses manufacturer Bayer of willfully concealing evidence of the risks of Yaz blood clots, which can lead to pulmonary embolism. The suit notes that “hundreds of reports of injury and death have been submitted to the FDA” regarding the damaging side effects of drospirenone, the active ingredient in Yaz and Yasmin, like Yaz deep vein thrombosis, thromboembolism, and pulmonary embolism.
Worse, says the Yasmin lawsuit, Bayer exaggerated the benefits of Yaz and Yasmin to attract more patients to the so-called “fourth-generation” birth control pill. Bayer ran advertisements that claimed that Yaz and Yasmin reduced symptoms of acne and PMS, and has been forced by the FDA to spend $20 million to retract that advertising. But these allegations are nothing compared to the claims made by patients who suffered side effects like Yaz pulmonary embolism after failing to receive adequate label warnings.